All issues > Volume 38(10); 1995

Original Article

J Korean Pediatr Soc. 1995;38(10):1378-1383. Published online October 15, 1995.

Prospective, Controlled Trial with Dipheny1-dimethy1-dicarboxylate in Children with Chronic Liver Diseses : The Effect on Lowering Serum Aminotransferase Levels

Ji Eun JE Wunon¹, Sang Gil SG An¹, Ki Moon KM Cha¹, Yong Min YM Chung¹, Hee Sup HS Kim¹, Hann H Tchah¹, Ho Jin HJ Park¹

¹Department of Pediatrics, Red Cross Hospital, Seoul, Korea

Abstract

Purpose
: The prospective cotrolled study was performed to identify the effect of the dipheny1-dimethy1-dicarboxylate(PMC) on lowering serum transaminases in children with chronic liver diseases.
Methods
: The twenty patients were paticipated in this study who were followed up in the Department of Pediatrics of the Seoul Red Cross Hospital because of the elevated levels of serum alaine aminotransferase(ALT) and aspartate aninotransferase(AST) for more than 6 months(>3 months in noeonatal hepatitis). These patients were divided into two groups after pairing according to histological diagnoses. Ten patients received PMC(Dosage 2.5-3.0 mg/kg/day) for 6 months and the other ten patients were enrolled as non-treated controls. Physical examination, liver function test, CBC and urinalysis were checked monthly.
Results
: In the PMC group serum ALT levels were decreased significantly from the 1st month(p<0.001) and the serum AST levels were decreased from the 3rd month(p<0.01) In contrast there were no significant changes of the levesls fo serum transaminases in the control group(p>0.05). There were significant differences in the mean ALT levels between the PMC group and the control group from the 1st month through to the 6th month(p<0.01). In the mean AST levels there were no significant differences between two groups except for the values at the 3rd and the 4th month(p<0.05). There were remarkable decreases of the levels of serum ALT and AST in the PMC group during the whole period of treatment as compared with the control group No. adverse effect were observed during PMC treatment.
Conclusion
: There were significant decreases in serum ALT and AST levels in children with chronic liver disease treated with PMC without any adverse effects.

Keywords :Chronic Liver Disease, Children, Treatment, dipheny1-dimethy1-dicarboxylate